Microbot Medical has transitioned from R&D to a commercialization phase with its FDA-cleared LIBERTY® Endovascular Robotic Surgical System, beginning full U.S. market release in early 2026. The May quarter filings document nascent sales progress highlighted by physician interest and pivotal trial account wins but confirm ongoing significant operating losses and limited prior revenue history. The company faces typical medtech start-up execution risks including manufacturing scale, regulatory compliance, and competitive pressures from established players. Near-term growth depends on expanding sales territories and broader clinical adoption while managing liquidity constraints.